BioTools Strategic Moves
Standard BioTools Secures $30M Illumina Buyout, Divests Mass Cytometry Business
Anonymous
Key Points
1
Mass Cytometry sale to Multiplex Bio includes a $5 million promissory note at 6% annual interest maturing in five years, plus up to $5 million in contingent consideration and up to $10 million in company-funded working capital financing if third-party financing is unavailable.
2
Illumina buyout: Standard BioTools will receive approximately $30 million in cash in exchange for waiving the 2026 SomaLogic-related earnout and terminating certain SomaLogic royalty and licensing obligations, effectively monetizing contingent liabilities tied to SomaLogic’s acquisition.
3
Multiplex Bio leadership will include Dr. Michael Johnson as CEO, Dr. Tom Villani as CTO, and Mr. Charles Coffman as COO; Johnson and Villani are co-founders of Visikol, bringing expertise in spatial biology and 3D tissue imaging to the new entity.
4
The U.S. Federal Trade Commission has granted early termination of the Hart-Scott-Rodino waiting period for the Treeline merger, allowing the merger process to proceed.
Standard BioTools (NASDAQ: LAB) announced two major deals this week. The company sold its Mass Cytometry business to a new firm called Multiplex Bio for a $5 million promissory note. Separately, it received about $30 million in cash from Illumina, according to Quiver Quant.
The two moves are designed to simplify the company's business ahead of its planned merger with Treeline Biosciences. The U.S. Federal Trade Commission also cleared a key hurdle for that merger, granting early termination of its standard waiting period, Stock Titan reported.
Illumina Pays $30 Million to Erase Future Obligations
Standard BioTools had the right to collect a large earnout payment from Illumina in 2026. That right was tied to Illumina's earlier acquisition of SomaLogic. Instead of waiting, the company agreed to waive that right now in exchange for $30 million in cash up front, according to Stock Titan.
The deal also ends certain royalty and licensing obligations tied to the SomaLogic acquisition. In plain terms, Standard BioTools gave up future payments it might have received — and in return, got a guaranteed $30 million today. TradingView described it as a settlement that cleans up contingent liabilities on the company's books.
Mass Cytometry Unit Sold to Newly Founded Multiplex Bio
The Mass Cytometry business — which includes CyTOF and Hyperion products — is being sold to Multiplex Bio. The buyer is a brand-new company founded by three executives: Dr. Michael Johnson as CEO, Dr. Tom Villani as CTO, and Charles Coffman as COO. Johnson and Villani previously co-founded Visikol, a firm focused on 3D tissue imaging, Investing.com noted.
The deal's price is a $5 million promissory note at 6% annual interest, maturing in five years. Multiplex Bio could also earn up to $5 million in extra payments tied to performance. If Multiplex Bio can't find outside funding, Standard BioTools has agreed to provide up to $10 million in working capital financing, according to TradingView.
Customers and Brand Name Stay the Same Under New Owner
Multiplex Bio will operate under the Standard BioTools brand name. It will also keep existing customer relationships and honor current service commitments. The goal is to make the transition invisible to customers who rely on CyTOF and Hyperion instruments, Quiver Quant reported.
Standard BioTools said the sale preserves continuity for its core product lines and customer base. At the same time, it frees the company to invest in next-generation multiplex platforms — technologies that can measure many biological signals at once in tissue samples.
Treeline Merger Moves Forward After FTC Clears Path
Both deals are timed around the company's planned merger with Treeline Biosciences. The FTC's early termination of the Hart-Scott-Rodino waiting period removes a major regulatory step. That waiting period is a standard review process required for large mergers under U.S. antitrust law, according to Stock Titan.
By selling the Mass Cytometry unit and resolving the Illumina obligations now, Standard BioTools enters the merger with a cleaner balance sheet. The company is shedding contingent liabilities and non-core assets before combining with Treeline, Quiver Quant reported.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
10
Articles
12
Reach
22
A
AnonymousAuthor
